Protein tyrosine kinases in dendritic cell-mediated anti-cancer immunity
Abstract
Dendritic cells (DCs), the most proficient antigen-presenting cells, bridge innate and adaptive immunity and are critical for anti-cancer immune surveillance. Their function is precisely regulated by protein tyrosine kinases (PTKs), which integrate signals from external stimuli and internal cellular stress to control DC maturation, migration, and antigen presentation. This review systematically synthesizes current knowledge on PTK roles in DC-mediated anti-tumor immunity, with a focused analysis of their differential expression and function across human and mouse DC subsets-including conventional (cDC1, cDC2), plasmacytoid (pDC), and monocyte-derived DCs. We highlight how specific PTK families (e.g., TAM, PDGFR, SRC, JAK) translate pathogen- and damage-associated signals into tailored immune responses. Furthermore, we discuss the dual impact of clinically approved PTK inhibitors on DC function, which can either enhance or suppress anti-tumor immunity depending on context. Finally, we evaluate translational strategies that combine PTK-targeted agents with DC-based vaccines or immune checkpoint blockade, offering a rationale for exploiting PTK-DC crosstalk to develop more effective combinatorial immunotherapies.
Related
- Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
- CD73-LNPs promote antitumor T-cell immunity via amplifying TLR3-mediated immunostimulatory dendritic cell activation
- Chronic XBP1s-mediated activation of the unfolded protein response impairs CD8+ T cell anti-tumor immunity
- Diacylglycerol Kinases Balance DAG Signaling to Control B Cell Maturation, Germinal Center Homeostasis, and Humoral Immunity
- 733 Macrophage-dendritic cell-T-cell tetrads orchestrate antitumor immunity and response to checkpoint blockade
BibTeX
@article{mao2026protein,
title = {{Protein tyrosine kinases in dendritic cell-mediated anti-cancer immunity}},
author = {Misha Mao and Liwei Zhao and Guido Kroemer and Oliver Kepp and Peng Liu},
journal = {Seminars in Immunology},
year = {2026},
month = sep,
doi = {10.1016/j.smim.2026.102037},
url = {https://hal.science/hal-05772029v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Protein tyrosine kinases in dendritic cell-mediated anti-cancer immunity
AU - Misha Mao
AU - Liwei Zhao
AU - Guido Kroemer
AU - Oliver Kepp
AU - Peng Liu
PY - 2026
DA - 2026/09/30
JO - Seminars in Immunology
DO - 10.1016/j.smim.2026.102037
UR - https://hal.science/hal-05772029v1
AB - Dendritic cells (DCs), the most proficient antigen-presenting cells, bridge innate and adaptive immunity and are critical for anti-cancer immune surveillance. Their function is precisely regulated by protein tyrosine kinases (PTKs), which integrate signals from external stimuli and internal cellular stress to control DC maturation, migration, and antigen presentation. This review systematically synthesizes current knowledge on PTK roles in DC-mediated anti-tumor immunity, with a focused analysis of their differential expression and function across human and mouse DC subsets-including conventional (cDC1, cDC2), plasmacytoid (pDC), and monocyte-derived DCs. We highlight how specific PTK families (e.g., TAM, PDGFR, SRC, JAK) translate pathogen- and damage-associated signals into tailored immune responses. Furthermore, we discuss the dual impact of clinically approved PTK inhibitors on DC function, which can either enhance or suppress anti-tumor immunity depending on context. Finally, we evaluate translational strategies that combine PTK-targeted agents with DC-based vaccines or immune checkpoint blockade, offering a rationale for exploiting PTK-DC crosstalk to develop more effective combinatorial immunotherapies.
SN - 1044-5323
SN - 1096-3618
ER -